BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
2 Lembo T, Saffioti F, Chiofalo B, Granese R, Filomia R, Grasso R, Triolo O, Raimondo G. Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy. Dig Liver Dis. 2017;49:1368-1372. [PMID: 28818677 DOI: 10.1016/j.dld.2017.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
3 Facente SN, Patel S, Hecht J, Wilson E, McFarland W, Page K, Vickerman P, Fraser H, Burk K, Morris MD. Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs. Clin Infect Dis 2021;73:e1290-5. [PMID: 33768236 DOI: 10.1093/cid/ciab261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Silva LD, Bering T, Rocha GA. The impact of nutrition on quality of life of patients with hepatitis C. Curr Opin Clin Nutr Metab Care 2017;20:420-5. [PMID: 28617708 DOI: 10.1097/MCO.0000000000000396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
5 Janda M, Mergenhagen KA. The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment. Psychosomatics 2017;58:624-32. [PMID: 28870488 DOI: 10.1016/j.psym.2017.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
6 Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, D'Assante R, Zappulo E, Borgia G, Gentile I. The role of curcumin in liver diseases. Arch Med Sci 2019;15:1608-20. [PMID: 31749891 DOI: 10.5114/aoms.2018.73596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Maraolo AE, Buonomo AR, Zappulo E, Scotto R, Pinchera B, Gentile I. Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. RRCT 2019;14:129-35. [DOI: 10.2174/1574887114666181204102516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opin Investig Drugs 2018;27:243-50. [PMID: 29271672 DOI: 10.1080/13543784.2018.1420780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. J Hepatol 2018;68:940-8. [PMID: 29288753 DOI: 10.1016/j.jhep.2017.12.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
11 Ramos-casals M, Zignego AL, Ferri C, Brito-zerón P, Retamozo S, Casato M, Lamprecht P, Mangia A, Saadoun D, Tzioufas AG, Younossi ZM, Cacoub P. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of Hepatology 2017;66:1282-99. [DOI: 10.1016/j.jhep.2017.02.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
12 Castro R, Crathorne L, Perazzo H, Silva J, Cooper C, Varley-Campbell J, Marinho DS, Haasova M, Veloso VG, Anderson R, Hyde C. Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol 2018;18:53. [PMID: 29895281 DOI: 10.1186/s12874-018-0515-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 McCready H, Kohno M, Kolessar M, Dennis L, Kriz D, Luber H, Anderson R, Chang M, Sasaki A, Flora K, Vandenbark A, Mitchell SH, Loftis JM, Hoffman WF, Huckans M. Functional MRI and delay discounting in patients infected with hepatitis C. J Neurovirol 2018;24:738-51. [PMID: 30298201 DOI: 10.1007/s13365-018-0670-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]